Could HPV shots start earlier? study tests vaccine in kids as young as 4
NCT ID NCT05329961
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study looks at whether a 2-dose regimen of the Gardasil 9 HPV vaccine, given 12 months apart, triggers a strong immune response in children aged 4 to 8. The vaccine is currently approved for ages 9 and up, but this research explores if starting earlier could provide protection against HPV-related cancers. Researchers will measure antibody levels over four years and monitor for side effects like swelling at the injection site.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gardasil 9 (9-valent HPV vaccine)
What this could lead to
If successful, this could support expanding HPV vaccination to children under 9, potentially preventing more HPV-related cancers later in life.
What could go wrong
This is an early exploratory study with only 155 children, so results may not apply broadly. The vaccine is not yet licensed for this age group, and immune responses may differ from older children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States